News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  17 November 2017  
 
Transglutaminase 2 Is a Direct Target Gene of YAP/TAZ-Letter
 
 




Authors
Chen-Ying Liu1,2*, Ajaybabu V. Pobbati2, Zhenyu Huang1, Long Cui1 and Wanjin Hong2

Author Affiliations
1 Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiaotong University School of   Medicine, Shanghai 200092, China

2 Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), 61   Biopolis Drive, Proteos, Singapore 138673, Singapore

Published in Cancer Res. 2017 Sep 1;77(17):4734-4735.  Published first August 15, 2017.

Abstract
Transglutaminase 2 (TG2) is a multifunctional protein that is overexpressed in multiple cancers and its expression levels positively correlate with metastasis and poor prognosis. Interestingly, TG2 is an activator of NF-kB and is also a direct target of NF-kB. It has been shown that knockdown of TG2 inhibits YAP activity. Here, in various cell lines, we show that TG2 is a direct target of YAP/TAZ; by upregulating TG2 expression, YAP/TAZ probably also forms a positive-feedback loop and amplifies oncogenic programs. TG2 has been a promising therapeutic target for many diseases, including cancer. Our results suggest that inhibition of TG2 could be a potent therapeutic strategy for the YAP/TAZ-active cancers.

Figure

Figure legend
: Analysis of Cancer Cell Line Encyclopedia (CCLE) microarray dataset reveals that the mRNA expression of TG2 correlates well with the known YAP/TAZ target genes and YAP/TAZ mRNA levels. The co-expression data was extracted from the cBioportal database. The values of Pearson’s correlation and Spearman’s correlation were generated and used for evaluating the significance of co-expression by the cBioportal.

For more information on Wanjin HONG's lab, please click here.